Table 2.
Multivariable-adjusted relative risks (RR) and 95% confidence intervals (CI) for the association between hormone therapy (HT) use and incident invasive lung cancer among 60,592 postmenopausal California Teachers Study participants
| Total | Never Smokers | Ever Smokers | ||||
|---|---|---|---|---|---|---|
| HT Use | N Total/Cases |
Adjusted1,2 RR (95% CI) |
N Total/Cases |
Adjusted1,3 RR (95% CI) |
N Total/Cases |
Adjusted1,4 RR (95% CI) |
| Ever HT Use | ||||||
| Never HT user | 15,405/216 | 1.00 | 9,912/55 | 1.00 | 5,493/161 | 1.00 |
| Ever HT user (Former and Recent HT users) | 45,187/511 | 0.95(0.80–1.13) | 27,226/129 | 1.06(0.76–1.50) | 17,961/382 | 0.93(0.77–1.14) |
| Former or Recent HT Use | ||||||
| Never HT user | 15,405/216 | 1.00 | 9,912/55 | 1.00 | 5,493/161 | 1.00 |
| Former E alone or E+P user | 9,716/147 | 0.98(0.79–1.21) | 5,871/43 | 1.21(0.80–1.82) | 3,845/104 | 0.93(0.72–1.19) |
| Recent E alone or E+P user | 35,471/364 | 0.94(0.78–1.13) | 21,355/86 | 0.98(0.67–1.43) | 14,116/278 | 0.94(0.76–1.16) |
| Type of HT Used | ||||||
| Never HT user | 15,405/216 | 1.00 | 9,912/55 | 1.00 | 5,493/161 | 1.00 |
| Former E alone or E+P user | 9,569/147 | 0.99(0.79–1.22) | 5,871/43 | 1.20(0.79–1.81) | 3,845/104 | 0.94(0.73–1.21) |
| Recent E alone therapy | 15,663/188 | 0.97(0.77–1.23) | 9,730/43 | 0.92(0.57–1.49) | 5,933/145 | 1.00(0.76–1.31) |
| Recent E+P combined therapy | 19,808/177 | 0.92(0.74–1.13) | 11,625/43 | 1.02(0.66–1.59) | 8,183/133 | 0.89(0.70–1.14) |
| Duration of HT Use | ||||||
| Never HT user | 15,405/216 | 1.00 | 9,912/55 | 1.00 | 5,493/161 | 1.00 |
| Ever HT user, ≤ 5 years duration | 19,670/167 | 0.93(0.76–1.15) | 12,205/48 | 1.08(0.72–1.63) | 7,465/119 | 0.91(0.71–1.16) |
| Ever HT user, 6–15 years duration | 13,866/151 | 0.92(0.74–1.14) | 8,081/42 | 1.18(0.76–1.82) | 5,785/109 | 0.85(0.66–1.10) |
| Ever HT user, ≥ 15 years duration | 9,122/151 | 0.95(0.75–1.20) | 5,399/30 | 0.88(0.54–1.45) | 3,723/121 | 0.98(0.76–1.28) |
| P-trend | 0.71 | 0.92 | 0.71 | |||
| Duration of HT Use | ||||||
| Never HT user | 15,405/216 | 1.00 | 9,912/55 | 1.00 | 5,493/161 | 1.00 |
| Former HT user | ||||||
| ≤ 5 years duration | 6,278/97 | 1.04(0.82–1.33) | 3,802/31 | 1.50(0.96–2.35) | 2,476/66 | 0.93(0.70–1.25) |
| 6–15 years duration | 2,038/31 | 0.89(0.60–1.31) | 1,224/8 | 0.93(0.42–2.09) | 814/23 | 0.87(0.55–1.36) |
| ≥ 15 years duration | 920/13 | 0.78(0.44–1.39) | 530/2 | 0.53(0.13–2.21) | 390/11 | 0.89(0.47–1.68) |
| P-trend | 0.46 | 0.99 | 0.48 | |||
| Recent HT user | ||||||
| ≤ 5 years duration | 13,392/70 | 0.81(0.60–1.09) | 8,403/17 | 0.69(0.37–1.30) | 4,989/53 | 0.86(0.61–1.20) |
| 6–15 years duration | 11,828/120/ | 0.92(0.72–1.17) | 6,857/34 | 1.25(0.77–2.02) | 4,971/86 | 0.84(0.63–1.12) |
| ≥ 15 years duration | 8,202138 | 0.92(0.72–1.17) | 4,869/28 | 0.93 (0.55–1.57) | 3,333/110 | 0.93(0.70–1.23) |
| P-trend | 0.56 | 0.60 | 0.40 | |||
| Years Since Last HT Use for Former Users | ||||||
| Never HT user | 15,405/216 | 1.00 | 9,912/55 | 1.00 | 5,493/161 | 1.00 |
| Former HT user, ≤ 5 years since last use | 3,746/47 | 1.11(0.80–1.55) | 2,176/10 | 1.11(0.55–2.25) | 1,570/37 | 1.12(0.77–1.63) |
| Former HT user, > 5 years since last use | 5,927/100 | 0.92(0.71–1.18) | 3,659/33 | 1.32(0.83–2.11) | 2,268/67 | 0.81(0.60–1.10) |
1
Stratified by age at baseline
2
Adjusted for race, smoking status/pack-years combination (never, former light, former heavy, current light, current heavy), type of menopause and BMI
3
Adjusted for race, type of menopause and BMI
4
Adjusted for race, smoking status/pack-years combination (former light, former heavy, current light, current heavy), type of menopause and BMI